Why It Matters

A fundamental clash over healthcare’s future unfolds at this hearing on December 10th as 165 million Americans with employer insurance face 6-7% premium increases in 2026, while 24 million ACA enrollees risk a 26% spike if subsidies expire.

The core tension: Republicans champion market competition and consumer choice to drive costs down. Democrats want government-regulated systems and price controls. Both sides see AI technology as potentially delivering $400 billion to $1.5 trillion in long-term savings, creating rare common ground—but the opening is narrow.

Key challenges: Telehealth expansion faces regulatory uncertainty with core Medicare provisions only extended through September 2025. Reimbursement rates remain too low to support AI-powered monitoring technology deployment, while a fragmented state-by-state patchwork limits innovation scaling.

Corporate interests at stake: Well-funded health-tech companies—including Viz.ai, Hello Heart, and Tendo Systems—are aggressively lobbying to shape legislation. Increased spending signals industry confidence this hearing could determine their operating environment and profitability.

The outcome will determine whether technology solutions reinforce existing market competition or integrate into expanding public healthcare programs—a distinction that will reverberate across U.S. healthcare for years.

Broader Context

The U.S. healthcare system faces an acute affordability crisis defining the hearing’s backdrop. Nearly half of American adults expect they cannot afford necessary care next year.

The ACA marketplace faces immediate instability with 24 million Americans facing potential 26% premium increases in 2026 if enhanced subsidies expire. The 165 million Americans with employer-sponsored insurance face projected 6-7% premium increases—the largest jump in 15 years, driven by prescription drug spending surging 9.4% and hospital consolidation limiting competition.

Paradoxically, the healthcare industry is in financial distress. UnitedHealth Group shares have plunged 44% year-over-year, limiting companies’ ability to invest in innovations.

Morgan Stanley Research estimates AI applications could create $400 billion to $1.5 trillion in savings by 2050, with the digital health market projecting growth to $55.8 billion in North America in 2025. However, regulatory uncertainty threatens investment—Congress extended core Medicare telehealth provisions only through September 2025.

Recent policy developments add complexity: An Executive Order on drug pricing was signed in May 2025, new price transparency rules took effect October 1, and Medicare drug price negotiation begins in 2026.

The Agenda

The December 10 hearing features witnesses from healthcare technology companies actively lobbying Congress on cost-reduction solutions.

Viz.ai Inc. increased lobbying spending from $80,000 in Q2 to $120,000 in Q3 2025, signaling serious investment in AI healthcare policy. Hello Heart Inc. maintained consistent $110,000 quarterly spending in Q2 and Q3 after registering as a new client. Tendo Systems Inc. spent $20,000 per quarter throughout 2025, demonstrating sustained policy interest.

These witnesses represent a health-tech industry seeking favorable regulatory treatment as lawmakers explore technology’s role in reducing costs.

Between The Lines

The House Oversight Subcommittee on Economic Growth, Energy Policy and Regulatory Affairs will hold the hearing, with committee dynamics shaped by starkly different member priorities.

Democratic positions: Rep. Ro Khanna (D-CA) champions universal coverage through his State-Based Universal Health Care Act, emphasizing Americans pay nearly three times more for drugs than other nations. Rep. Maxwell Frost (D-FL) warns Republican proposals would increase healthcare costs.

Republican positions: Rep. Gary Palmer (R-AL) introduced the New Health Options Act, establishing ACA-separate marketplaces emphasizing competition and price transparency. Rep. Scott Perry (R-PA) supports ending pandemic-era subsidies and backing rural health programs.

The fundamental divide centers on market-driven solutions versus government-regulated approaches to technology’s role in cost reduction.

Competitive Landscape

Health-tech companies are making significant financial pushes to influence federal policy ahead of the December 10 hearing.

Viz.ai nearly doubled lobbying spending from $80,000 in Q2 to $120,000 in Q3 2025. Hello Heart maintained consistent $110,000 spending in both Q2 and Q3. Tendo Systems deployed steady $20,000 quarterly pressure throughout 2025.

Notably, Memora Health terminated its lobbying registration in the third quarter of 2025 after minimal activity.

No specific bills are mentioned in lobbying filings—companies focus on general advocacy around healthcare technology and AI policy rather than targeted legislation.

The Bottom Line

The December 10 House Oversight subcommittee hearing examines how technology can reduce healthcare costs amid a national affordability crisis. With 24 million Americans facing potential 26% premium increases if ACA subsidies expire and employer premiums jumping 6-7%, the stakes couldn’t be higher.

The partisan divide will dominate discussion. Democrats will push for technology strengthening public programs and controlling drug prices. Republicans will emphasize market competition and consumer choice.

Health-tech companies are positioning as key players, with Viz.ai nearly doubling lobbying spending while Hello Heart and Tendo Systems sustain steady advocacy. Though AI could generate $400 billion to $1.5 trillion in healthcare savings by 2050, regulatory uncertainty around telehealth reimbursement remains a significant deployment barrier.

Access the Legis1 platform for comprehensive political news, data, and insights.

Spot something wrong? Report an issue with this article